Chandan Saw, DO
Pulmonary Disease · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 21
- 5 carriers
- Office
- 1
Offices
1 location · Physician Services at El Camino Hospital · 10 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
21 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Saw’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
21 of 21 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$275,421
Medicare paid this office $275,421 for 482 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 410 | $137,258 | $115 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 74 | $52,546 | $107 |
| Critical care, first 30-74 minutes | 17 | $17,940 | $187 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 90 | $17,444 | $156 |
| New patient visit (60+ min) | 95 | $17,309 | $182 |
See all 13 services
| Return visit (30+ min) | 410 | $137,258 | $115 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 74 | $52,546 | $107 |
| Critical care, first 30-74 minutes | 17 | $17,940 | $187 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 90 | $17,444 | $156 |
| New patient visit (60+ min) | 95 | $17,309 | $182 |
| Sleep study including heart rate, breathing, and sleep time | 53 | $13,981 | $143 |
| Transitional care management services for problem of at least moderate complexity | 37 | $8,589 | $204 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 49 | $4,540 | $71 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 98 | $1,687 | $15 |
| Test for exercise-induced lung stress | 56 | $1,078 | $19 |
| Test to determine lung volumes using sensors | 80 | $801 | $10 |
| Test to examine how well the lungs exchange gases | 83 | $600 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 26 | $208 | $8 |
Who their Medicare patients are
482 Original Medicare patients in 2024. Average age 80 · Women 47% · Also on Medicaid 7% · Health risk score 1.60. At or below the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Coronary heart disease 46% · COPD 42% · Atrial fibrillation 37% · Heart failure 31% · Diabetes 30% · Cancer 27% · Chronic kidney disease 25% · Depression 17% · Stroke 11% · Dementia 10%.
The office billed $1,120,419, Medicare allowed $361,613 and paid $275,421; for 2,588 services of 21 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 482 | 2,588 | 80 | 1.60 | $1,120,419 | $275,421 |
| 2023 | 504 | 2,972 | 80 | 1.78 | $1,197,560 | $308,598 |
| 2022 | 490 | 2,538 | 80 | 1.89 | $957,936 | $258,959 |
| 2021 | 506 | 2,355 | 79 | 1.75 | $653,283 | $255,815 |
| 2020 | 527 | 2,053 | 79 | 1.87 | $504,258 | $214,037 |
| 2019 | 583 | 2,364 | 79 | 2.11 | $601,509 | $233,525 |
| 2018 | 605 | 2,493 | 78 | 2.02 | $631,761 | $242,495 |
| 2017 | 591 | 2,685 | 79 | 1.97 | $643,549 | $249,127 |
| 2016 | 572 | 2,436 | 78 | 1.93 | $622,423 | $237,572 |
| 2015 | 604 | 2,444 | 79 | 1.91 | $635,445 | $247,827 |
| 2014 | 603 | 2,379 | 79 | 1.98 | $624,062 | $245,205 |
| 2013 | 626 | 2,639 | 78 | 2.02 | $687,320 | $262,026 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Return visit (30+ min) | 391 | $132,750 | $115 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 106 | $88,110 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 116 | $23,753 | $155 |
| New patient visit (60+ min) | 89 | $17,530 | $197 |
| Sleep study including heart rate, breathing, and sleep time | 36 | $11,255 | $154 |
| Transitional care management services for problem of at least moderate complexity | 44 | $11,152 | $199 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 88 | $9,482 | $71 |
| Critical care, first 30-74 minutes | 16 | $8,082 | $188 |
| Test for exercise-induced lung stress | 94 | $1,885 | $19 |
| Test to determine lung volumes using sensors | 123 | $1,228 | $10 |
| Test to examine how well the lungs exchange gases | 126 | $916 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 46 | $366 | $8 |
| Test to measure expiratory airflow and volume | 12 | $88 | $7 |
2022: 12 services
| Return visit (30+ min) | 368 | $117,583 | $115 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 94 | $65,093 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 96 | $22,385 | $179 |
| New patient visit (60+ min) | 71 | $13,860 | $195 |
| Critical care, first 30-74 minutes | 33 | $11,497 | $195 |
| Sleep study including heart rate, breathing, and sleep time | 27 | $8,450 | $166 |
| Transitional care management services for problem of at least moderate complexity | 32 | $7,615 | $190 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 62 | $5,860 | $64 |
| Test for exercise-induced lung stress | 76 | $1,594 | $20 |
| Test to determine lung volumes using sensors | 104 | $1,123 | $10 |
| Test to examine how well the lungs exchange gases | 104 | $831 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 36 | $336 | $9 |
2021: 12 services
| Return visit (30+ min) | 371 | $128,444 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 91 | $40,746 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 94 | $24,952 | $183 |
| Critical care, first 30-74 minutes | 62 | $22,938 | $198 |
| Transitional care management services for problem of at least moderate complexity | 39 | $9,963 | $203 |
| New patient visit (60+ min) | 47 | $9,293 | $198 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 17 | $5,640 | $171 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 58 | $5,082 | $65 |
| Test for exercise-induced lung stress | 71 | $1,532 | $21 |
| Test to determine lung volumes using sensors | 92 | $1,082 | $11 |
| Test to examine how well the lungs exchange gases | 93 | $800 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 26 | $248 | $10 |
2020: 12 services
| Return visit (30+ min) | 401 | $109,396 | $98 |
| Critical care, first 30-74 minutes | 67 | $33,904 | $202 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $21,858 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 61 | $13,189 | $188 |
| New patient visit (60+ min) | 68 | $12,076 | $178 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 21 | $8,868 | $222 |
| Transitional care management services for problem of at least moderate complexity | 28 | $5,851 | $177 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 38 | $3,987 | $68 |
| Test to determine lung volumes using sensors | 76 | $860 | $11 |
| Test to examine how well the lungs exchange gases | 76 | $641 | $8 |
| Test for exercise-induced lung stress | 19 | $424 | $19 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 34 | $412 | $12 |
2019: 14 services
| Return visit (30+ min) | 415 | $100,040 | $91 |
| Critical care, first 30-74 minutes | 110 | $48,723 | $189 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 91 | $25,006 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 76 | $15,928 | $175 |
| New patient visit (60+ min) | 74 | $12,678 | $171 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 24 | $10,216 | $213 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 71 | $8,813 | $63 |
| Transitional care management services for problem of at least moderate complexity | 37 | $6,176 | $144 |
| Test to determine lung volumes using sensors | 82 | $890 | $10 |
| Influenza vaccine split virus, preservative free | 15 | $803 | $54 |
| Test for exercise-induced lung stress | 39 | $793 | $19 |
| Test to examine how well the lungs exchange gases | 86 | $706 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 49 | $579 | $12 |
| Administration of influenza virus vaccine | 15 | $308 | $21 |
2018: 15 services
| Return visit (30+ min) | 421 | $105,779 | $91 |
| Critical care, first 30-74 minutes | 123 | $52,317 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 86 | $20,009 | $89 |
| New patient visit (60+ min) | 90 | $14,804 | $164 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 60 | $14,344 | $173 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 30 | $12,108 | $205 |
| Transitional care management services for problem of at least moderate complexity | 34 | $6,684 | $145 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 39 | $6,085 | $62 |
| Critical care, each additional 30 minutes | 24 | $2,889 | $93 |
| Test for exercise-induced lung stress | 60 | $1,234 | $19 |
| Test to determine lung volumes using sensors | 106 | $1,188 | $11 |
| Test to examine how well the lungs exchange gases | 105 | $869 | $8 |
| Influenza vaccine split virus, preservative free | 19 | $652 | $34 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 57 | $649 | $11 |
| Administration of influenza virus vaccine | 19 | $489 | $26 |
2017: 16 services
| Return visit (30+ min) | 415 | $105,023 | $89 |
| Critical care, first 30-74 minutes | 98 | $38,409 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 103 | $32,238 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 84 | $18,945 | $172 |
| New patient visit (60+ min) | 87 | $15,217 | $175 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 67 | $13,170 | $62 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 23 | $9,597 | $204 |
| Transitional care management services for problem of at least moderate complexity | 42 | $7,961 | $147 |
| Critical care, each additional 30 minutes | 18 | $1,776 | $93 |
| Pulmonary exercise testing | 50 | $1,501 | $27 |
| Test to determine lung volumes using sensors | 102 | $1,198 | $11 |
| Test to examine how well the lungs exchange gases | 101 | $880 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 57 | $671 | $11 |
| Influenza vaccine split virus, preservative free | 17 | $583 | $34 |
| Administration of influenza virus vaccine | 17 | $549 | $32 |
| Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | 13 | $397 | $31 |
2016: 16 services
| Return visit (30+ min) | 404 | $104,104 | $88 |
| Critical care, first 30-74 minutes | 110 | $46,475 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 97 | $27,268 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 64 | $13,186 | $171 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 31 | $12,093 | $205 |
| New patient visit (60+ min) | 70 | $11,936 | $171 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 61 | $10,750 | $61 |
| Transitional care management services for problem of at least moderate complexity | 17 | $2,667 | $148 |
| Critical care, each additional 30 minutes | 24 | $2,518 | $93 |
| Advance care planning, first 30 minutes | 13 | $954 | $73 |
| Influenza vaccine split virus, preservative free | 25 | $858 | $34 |
| Administration of influenza virus vaccine | 28 | $843 | $30 |
| Test to determine lung volumes using sensors | 63 | $720 | $11 |
| Test to examine how well the lungs exchange gases | 61 | $507 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 37 | $447 | $12 |
| Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | 14 | $427 | $31 |
2015: 10 services
| Return visit (30+ min) | 421 | $107,343 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 166 | $39,242 | $88 |
| Critical care, first 30-74 minutes | 103 | $33,743 | $186 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 112 | $23,032 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 102 | $17,651 | $62 |
| New patient visit (60+ min) | 93 | $16,473 | $177 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 20 | $7,369 | $194 |
| Critical care, each additional 30 minutes | 14 | $1,494 | $93 |
| Administration of influenza virus vaccine | 19 | $699 | $32 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | 12 | $109 | $8 |
2014: 9 services
| Return visit (30+ min) | 386 | $109,126 | $90 |
| Critical care, first 30-74 minutes | 89 | $32,310 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 153 | $31,162 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 100 | $19,992 | $171 |
| New patient visit (60+ min) | 110 | $18,976 | $173 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 89 | $17,284 | $61 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 34 | $13,649 | $204 |
| Administration of influenza virus vaccine | 26 | $809 | $31 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | 16 | $135 | $8 |
2013: 13 services
| Return visit (30+ min) | 379 | $104,485 | $91 |
| Critical care, first 30-74 minutes | 113 | $39,321 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 196 | $36,855 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 113 | $20,878 | $166 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 106 | $18,712 | $59 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 44 | $17,892 | $203 |
| New patient visit (60+ min) | 97 | $16,503 | $170 |
| Critical care, each additional 30 minutes | 14 | $1,369 | $91 |
| Administration of influenza virus vaccine | 18 | $578 | $32 |
| Test to determine lung volumes using sensors | 45 | $524 | $12 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 37 | $428 | $12 |
| Test to examine how well the lungs exchange gases | 45 | $384 | $9 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | 18 | $151 | $8 |
Drugs they prescribed that Part D paid
$464,554
Pharmacies billed $464,554 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,114) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
314 generic and 800 brand-name prescriptions · $464,554 in drug cost · 40 antibiotic prescriptions to 26 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trelegy Ellipta | 302 | $242,729 | $804 |
| Breo Ellipta | 151 | $78,443 | $519 |
| Anoro Ellipta | 53 | $34,255 | $646 |
| Spiriva Respimat | 17 | $17,504 | $1,030 |
| Spiriva Handihaler | 15 | $16,537 | $1,102 |
See all 15 drugs
| Trelegy Ellipta | 302 | $242,729 | $804 |
| Breo Ellipta | 151 | $78,443 | $519 |
| Anoro Ellipta | 53 | $34,255 | $646 |
| Spiriva Respimat | 17 | $17,504 | $1,030 |
| Spiriva Handihaler | 15 | $16,537 | $1,102 |
| Stiolto Respimat | 13 | $7,987 | $614 |
| Advair Hfa | 17 | $6,320 | $372 |
| Albuterol Sulfate Hfa | 225 | $5,786 | $26 |
| Symbicort | 22 | $5,153 | $234 |
| Wixela Inhub | 21 | $4,591 | $219 |
| Arnuity Ellipta | 14 | $3,741 | $267 |
| Levalbuterol Tartrate Hfa | 17 | $888 | $52 |
| Prednisone | 64 | $436 | $7 |
| Montelukast | 28 | $180 | $6 |
| Azithromycin | 25 | $131 | $5 |
Year by year
| 2024 | 1,114 | 177 | 0% (0) | 72% | $464,554 |
| 2023 | 1,051 | 189 | 0% (0) | 74% | $494,237 |
| 2022 | 941 | 166 | 0% (0) | 72% | $462,414 |
| 2021 | 1,037 | 171 | 0% (0) | 74% | $595,337 |
| 2020 | 1,104 | 156 | 0% (0) | 72% | $612,946 |
| 2019 | 1,042 | 166 | 0% (0) | 78% | $511,695 |
| 2018 | 1,177 | 174 | 0% (0) | 81% | $466,423 |
| 2017 | 1,135 | 167 | None | 81% | $359,575 |
| 2016 | 1,100 | 174 | 0% (0) | 79% | $311,714 |
| 2015 | 1,156 | 163 | 0% (0) | 78% | $290,035 |
| 2014 | 1,185 | 159 | 0% (0) | 73% | $253,602 |
| 2013 | 1,204 | 166 | None | 73% | $232,131 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Trelegy Ellipta | 232 | $218,667 | $943 |
| Breo Ellipta | 111 | $72,288 | $651 |
| Anoro Ellipta | 85 | $53,239 | $626 |
| Symbicort | 90 | $44,620 | $496 |
| Spiriva Handihaler | 25 | $25,761 | $1,030 |
| Spiriva Respimat | 18 | $16,284 | $905 |
| Incruse Ellipta | 11 | $4,863 | $442 |
| Albuterol Sulfate Hfa | 153 | $4,442 | $29 |
| Fluticasone-Salmeterol | 19 | $3,897 | $205 |
| Ventolin Hfa | 46 | $3,325 | $72 |
| Levalbuterol Tartrate Hfa | 15 | $822 | $55 |
| Prednisone | 85 | $488 | $6 |
| Montelukast | 14 | $381 | $27 |
| Amoxicillin-Clavulanate Potass | 14 | $224 | $16 |
| Azithromycin | 19 | $114 | $6 |
2022: 15 drugs
| Trelegy Ellipta | 176 | $171,472 | $974 |
| Breo Ellipta | 126 | $81,492 | $647 |
| Symbicort | 97 | $55,252 | $570 |
| Anoro Ellipta | 76 | $44,945 | $591 |
| Spiriva Handihaler | 37 | $39,761 | $1,075 |
| Spiriva Respimat | 19 | $15,111 | $795 |
| Wixela Inhub | 14 | $7,050 | $504 |
| Fluticasone-Salmeterol | 19 | $6,048 | $318 |
| Fluticasone-Vilanterol | 12 | $4,796 | $400 |
| Albuterol Sulfate Hfa | 92 | $3,592 | $39 |
| Ventolin Hfa | 28 | $2,490 | $89 |
| Prednisone | 112 | $817 | $7 |
| Montelukast | 16 | $407 | $25 |
| Amoxicillin-Clavulanate Potass | 17 | $204 | $12 |
| Azithromycin | 16 | $84 | $5 |
2021: 13 drugs
| Trelegy Ellipta | 157 | $120,676 | $769 |
| Breo Ellipta | 179 | $110,346 | $616 |
| Spiriva | 66 | $70,341 | $1,066 |
| Symbicort | 97 | $57,744 | $595 |
| Anoro Ellipta | 52 | $35,069 | $674 |
| Spiriva Respimat | 24 | $19,820 | $826 |
| Incruse Ellipta | 16 | $15,009 | $938 |
| Wixela Inhub | 27 | $12,405 | $459 |
| Albuterol Sulfate Hfa | 111 | $5,455 | $49 |
| Ventolin Hfa | 26 | $2,564 | $99 |
| Prednisone | 108 | $828 | $8 |
| Montelukast | 19 | $239 | $13 |
| Azithromycin | 25 | $158 | $6 |
2020: 17 drugs
| Ofev | 15 | $160,162 | $10,677 |
| Breo Ellipta | 182 | $110,178 | $605 |
| Trelegy Ellipta | 117 | $88,410 | $756 |
| Spiriva | 58 | $59,758 | $1,030 |
| Symbicort | 64 | $36,347 | $568 |
| Spiriva Respimat | 47 | $31,933 | $679 |
| Anoro Ellipta | 61 | $31,412 | $515 |
| Incruse Ellipta | 25 | $20,428 | $817 |
| Wixela Inhub | 46 | $17,460 | $380 |
| Flovent Hfa | 14 | $5,341 | $382 |
| Dulera | 17 | $5,279 | $311 |
| Albuterol Sulfate Hfa | 97 | $5,190 | $54 |
| Proair Hfa | 32 | $5,125 | $160 |
| Ventolin Hfa | 43 | $3,763 | $88 |
| Prednisone | 134 | $1,025 | $8 |
| Montelukast | 22 | $348 | $16 |
| Azithromycin | 33 | $274 | $8 |
2019: 16 drugs
| Breo Ellipta | 175 | $102,228 | $584 |
| Spiriva | 93 | $80,077 | $861 |
| Trelegy Ellipta | 81 | $54,249 | $670 |
| Advair Diskus | 42 | $26,265 | $625 |
| Spiriva Respimat | 51 | $26,258 | $515 |
| Anoro Ellipta | 41 | $23,465 | $572 |
| Symbicort | 47 | $20,649 | $439 |
| Incruse Ellipta | 26 | $16,590 | $638 |
| Wixela Inhub | 33 | $10,023 | $304 |
| Proair Hfa | 79 | $7,535 | $95 |
| Ventolin Hfa | 52 | $5,002 | $96 |
| Pulmicort Flexhaler | 13 | $2,940 | $226 |
| Albuterol Sulfate Hfa | 21 | $1,007 | $48 |
| Prednisone | 108 | $618 | $6 |
| Montelukast | 17 | $373 | $22 |
| Azithromycin | 38 | $311 | $8 |
2018: 16 drugs
| Breo Ellipta | 212 | $104,188 | $491 |
| Spiriva | 118 | $80,043 | $678 |
| Advair Diskus | 109 | $62,917 | $577 |
| Anoro Ellipta | 58 | $34,826 | $600 |
| Symbicort | 58 | $22,037 | $380 |
| Incruse Ellipta | 44 | $21,430 | $487 |
| Spiriva Respimat | 34 | $19,036 | $560 |
| Proair Hfa | 102 | $8,698 | $85 |
| Trelegy Ellipta | 13 | $6,887 | $530 |
| Ventolin Hfa | 83 | $5,733 | $69 |
| Levalbuterol Tartrate Hfa | 24 | $2,095 | $87 |
| Proair Respiclick | 18 | $1,477 | $82 |
| Prednisone | 117 | $978 | $8 |
| Montelukast | 21 | $467 | $22 |
| Azithromycin | 36 | $402 | $11 |
| Warfarin | 14 | $132 | $9 |
2017: 18 drugs
| Spiriva | 148 | $84,086 | $568 |
| Advair Diskus | 125 | $68,866 | $551 |
| Breo Ellipta | 163 | $67,879 | $416 |
| Anoro Ellipta | 63 | $29,244 | $464 |
| Incruse Ellipta | 52 | $21,239 | $408 |
| Symbicort | 49 | $16,755 | $342 |
| Spiriva Respimat | 26 | $13,413 | $516 |
| Proair Hfa | 117 | $9,801 | $84 |
| Qvar | 26 | $7,687 | $296 |
| Dulera | 11 | $3,139 | $285 |
| Ventolin Hfa | 41 | $2,229 | $54 |
| Proair Respiclick | 17 | $1,426 | $84 |
| Levalbuterol Tartrate Hfa | 13 | $1,193 | $92 |
| Prednisone | 102 | $913 | $9 |
| Montelukast | 16 | $344 | $21 |
| Azithromycin | 32 | $294 | $9 |
| Warfarin | 20 | $264 | $13 |
| Amoxicillin-Clavulanate Potass | 11 | $136 | $12 |
2016: 18 drugs
| Spiriva | 189 | $86,253 | $456 |
| Advair Diskus | 152 | $69,752 | $459 |
| Breo Ellipta | 133 | $50,423 | $379 |
| Symbicort | 69 | $24,619 | $357 |
| Spiriva Respimat | 26 | $13,659 | $525 |
| Incruse Ellipta | 22 | $9,316 | $423 |
| Anoro Ellipta | 27 | $8,533 | $316 |
| Qvar | 30 | $7,801 | $260 |
| Combivent Respimat | 17 | $7,741 | $455 |
| Proair Hfa | 106 | $7,234 | $68 |
| Ventolin Hfa | 25 | $1,503 | $60 |
| Xopenex Hfa | 12 | $1,456 | $121 |
| Proair Respiclick | 12 | $1,018 | $85 |
| Prednisone | 91 | $788 | $9 |
| Montelukast | 27 | $736 | $27 |
| Azithromycin | 29 | $272 | $9 |
| Amoxicillin-Clavulanate Potass | 15 | $189 | $13 |
| Warfarin | 18 | $143 | $8 |
2015: 17 drugs
| Spiriva | 236 | $94,711 | $401 |
| Advair Diskus | 207 | $80,167 | $387 |
| Breo Ellipta | 105 | $38,896 | $370 |
| Symbicort | 69 | $23,842 | $346 |
| Qvar | 38 | $10,618 | $279 |
| Proair Hfa | 127 | $8,497 | $67 |
| Combivent Respimat | 11 | $5,823 | $529 |
| Spiriva Respimat | 13 | $5,329 | $410 |
| Xopenex Hfa | 23 | $1,866 | $81 |
| Montelukast | 29 | $1,420 | $49 |
| Prednisone | 80 | $576 | $7 |
| Atorvastatin | 15 | $261 | $17 |
| Warfarin | 23 | $239 | $10 |
| Amoxicillin-Clavulanate Potass | 13 | $239 | $18 |
| Azithromycin | 24 | $236 | $10 |
| Levothyroxine | 11 | $151 | $14 |
| Losartan | 11 | $56 | $5 |
2014: 18 drugs
| Spiriva | 272 | $102,528 | $377 |
| Advair Diskus | 201 | $76,562 | $381 |
| Symbicort | 77 | $21,990 | $286 |
| Qvar | 43 | $9,880 | $230 |
| Proair Hfa | 130 | $8,554 | $66 |
| Breo Ellipta | 20 | $6,491 | $325 |
| Combivent Respimat | 16 | $5,684 | $355 |
| Montelukast | 34 | $1,938 | $57 |
| Xopenex Hfa | 19 | $1,347 | $71 |
| Prednisone | 116 | $976 | $8 |
| Ipratropium-Albuterol | 12 | $762 | $64 |
| Azithromycin | 35 | $294 | $8 |
| Amox Tr-Potassium Clavulanate | 15 | $259 | $17 |
| Levothyroxine | 13 | $129 | $10 |
| Atorvastatin | 13 | $107 | $8 |
| Atenolol | 11 | $84 | $8 |
| Losartan | 14 | $83 | $6 |
| Amlodipine Besylate | 11 | $59 | $5 |
2013: 18 drugs
| Spiriva | 269 | $89,917 | $334 |
| Advair Diskus | 225 | $74,708 | $332 |
| Symbicort | 101 | $27,660 | $274 |
| Qvar | 36 | $8,061 | $224 |
| Proair Hfa | 114 | $7,216 | $63 |
| Montelukast | 39 | $2,617 | $67 |
| Daliresp | 12 | $2,430 | $203 |
| Ventolin Hfa | 34 | $1,884 | $55 |
| Xopenex Hfa | 19 | $1,163 | $61 |
| Ipratropium-Albuterol | 14 | $1,028 | $73 |
| Prednisone | 107 | $463 | $4 |
| Azithromycin | 44 | $413 | $9 |
| Amox Tr-Potassium Clavulanate | 15 | $403 | $27 |
| Omeprazole | 14 | $284 | $20 |
| Losartan | 11 | $129 | $12 |
| Atenolol | 11 | $115 | $10 |
| Simvastatin | 12 | $63 | $5 |
| Zolpidem | 12 | $54 | $4 |
Money from drug and device companies
$752 in 2025
| 2025 | 8 | 35 | None | $752 |
| 2024 | 5 | 37 | None | $723 |
| 2023 | 5 | 46 | None | $839 |
| 2022 | 5 | 45 | None | $842 |
| 2021 | 5 | 46 | None | $673 |
| 2020 | 5 | 45 | None | $839 |
| 2019 | 3 | 7 | None | $191 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| GlaxoSmithKline | Trelegy Ellipta | $273 | 16 payments
|
| AstraZeneca Pharmaceuticals LP | Airsupra | $157 | 5 payments
|
| Verona Pharma | Ohtuvayre | $87 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jascayd | $85 | 3 payments
|
| Insmed | Brinsupri | $64 | 3 payments
|
| Electromed | Smartvest | $38 | 3 payments
|
See all 35 published payments
| Insmed | Meals · 2025-12-31 | Arikayce | $29 |
| Insmed | Education · 2025-12-30 | Brinsupri | $17 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-11 | Jascayd | $29 |
| Electromed | Meals · 2025-12-09 | Smartvest | $19 |
| Electromed | Meals · 2025-12-09 | Smartvest | $2 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-26 | Airsupra | $35 |
| Inspire Medical Systems | Meals · 2025-11-19 | Inspire | $32 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-13 | Jascayd | $28 |
| GlaxoSmithKline | Meals · 2025-11-04 | Trelegy Ellipta | $30 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-21 | Jascayd | $29 |
| Insmed | Education · 2025-10-20 | Brinsupri | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-15 | Airsupra | $30 |
| Verona Pharma | Meals · 2025-10-07 | Ohtuvayre | $26 |
| GlaxoSmithKline | Meals · 2025-09-30 | Nucala | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-23 | Breztri | $29 |
| Lilly USA | Meals · 2025-08-26 | Zepbound | $17 |
| GlaxoSmithKline | Meals · 2025-08-14 | Trelegy Ellipta | $7 |
| GlaxoSmithKline | Meals · 2025-07-15 | Nucala | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-09 | Airsupra | $33 |
| GlaxoSmithKline | Meals · 2025-06-03 | Trelegy Ellipta | $3 |
| GlaxoSmithKline | Meals · 2025-06-03 | Trelegy Ellipta | $27 |
| GlaxoSmithKline | Meals · 2025-05-20 | Nucala | $31 |
| Verona Pharma | Meals · 2025-05-13 | Ohtuvayre | $29 |
| GlaxoSmithKline | Meals · 2025-05-01 | Trelegy Ellipta | $8 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-30 | Airsupra | $30 |
| GlaxoSmithKline | Meals · 2025-04-24 | Trelegy Ellipta | $8 |
| GlaxoSmithKline | Meals · 2025-04-08 | Nucala | $18 |
| GlaxoSmithKline | Meals · 2025-03-11 | Trelegy Ellipta | $25 |
| Electromed | Meals · 2025-03-05 | Smartvest | $16 |
| GlaxoSmithKline | Meals · 2025-03-03 | Nucala | $5 |
| GlaxoSmithKline | Meals · 2025-02-27 | Trelegy Ellipta | $8 |
| GlaxoSmithKline | Meals · 2025-02-04 | Trelegy Ellipta | $29 |
| GlaxoSmithKline | Meals · 2025-01-30 | Nucala | $8 |
| GlaxoSmithKline | Meals · 2025-01-30 | Nucala | $4 |
| Verona Pharma | Meals · 2025-01-28 | Ohtuvayre | $31 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $723
| GlaxoSmithKline | Nucala | $308 | 20 payments
|
| AstraZeneca Pharmaceuticals LP | Airsupra | $213 | 7 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $86 | 3 payments
|
| Philips North America | (8874) Incourage | $84 | 3 payments
|
| Baxter Healthcare | Hillrom - Vest System Model 105 Home Care | $32 | 1 payment
|
2023: $839
| GlaxoSmithKline | Trelegy Ellipta | $352 | 23 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $233 | 11 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $169 | 8 payments
|
| Mylan Specialty L.P. | Yupelri | $65 | 3 payments
|
| Philips Electronics North America | (8874) Incourage | $19 | 1 payment
|
2022: $842
| GlaxoSmithKline | Trelegy Ellipta | $374 | 23 payments
|
| Boehringer Ingelheim Pharmaceuticals | Stiolto Respimat | $225 | 12 payments
|
| Abbvie | Avycaz | $89 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $80 | 4 payments
|
| Mylan Specialty L.P. | Yupelri | $74 | 3 payments
|
2021: $673
| Boehringer Ingelheim Pharmaceuticals | Stiolto Respimat | $320 | 19 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $228 | 20 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $92 | 5 payments
|
| Philips Electronics North America | (9369) Reusable Vest | $18 | 1 payment
|
| Insmed | Arikayce | $15 | 1 payment
|
2020: $839
| Boehringer Ingelheim Pharmaceuticals | Ofev | $359 | 16 payments
|
| GlaxoSmithKline | Anoro Ellipta | $310 | 19 payments
|
| AstraZeneca Pharmaceuticals LP | Symbicort | $116 | 6 payments
|
| Insmed | Arikayce | $30 | 2 payments
|
| Mylan Specialty L.P. | Yupelri | $25 | 1 payment
|
2019: $191
| AstraZeneca Pharmaceuticals LP | Fasenra | $101 | 3 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $59 | 2 payments
|
| Insmed | Arikayce | $31 | 2 payments
|
Checkups this office reported
8 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 98.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Advance care plan on fileOlder patients with an advance care plan or a documented conversation about one | 100%That's most of the people this applied to. | 503 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 83%That's most of the people this applied to. | 217 |
| Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator TherapyAs Medicare defines this measure | 100% | 47 |
| Medications listed in the chartVisits where the current medication list was documented | 100%That's most of the people this applied to. | 2,096 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 97%That's most of the people this applied to. | 393 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 97%That's most of the people this applied to. | 235 |
| Sleep Apnea: Assessment of Adherence to Positive Airway Pressure TherapyAs Medicare defines this measure | 100% | 113 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 100%That's most of the people this applied to. | 699 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Did a security review of patient data
- Implementation of improvements that contribute to more timely communication of test results
- Implementation of medication management practice improvements
- ONC-ACB Surveillance Attestation
- Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
- Reports immunizations to the state registry
- Exempt from electronic case reporting
- Exempt from query of the prescription drug monitoring program (pdmp)
- Exempt from support electronic referral loops by receiving and reconciling health information
- Exempt from support electronic referral loops by sending health information
Professional record
- NPI
- 1710925284
- Licence
- CA 20A8848
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Internal medicine (207R00000X); Federal specialty code 207RC0200X (207RC0200X); Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- 2495 Hospital Dr Ste 660, Mountain View, CA, 94040
- NPI first listed
- 2006-06-04
- NPI last updated
- 2022-08-04
- NPI record certified
- 2022-08-04
This is when the NPI record was last certified, not a medical board exam.